In recent years, studies have shown that obesity-induced non-alcoholic fatty liver diseases (NAFLDs) can lead to increased levels of liver enzymes such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) and pose a significant risk of metabolic disorders and mortality [13]. This evidence concerns the gene GPT and metabolic disease.